Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
2.18
Dollar change
-0.02
Percentage change
-0.91
%
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand80.99M Perf Week3.81%
Market Cap204.29M Forward P/E- EPS next Y-0.92 Insider Trans- Shs Float- Perf Month-30.79%
Income- PEG- EPS next Q- Inst Own0.07% Short Float- Perf Quarter-3.11%
Sales- P/S- EPS this Y87.88% Inst Trans0.24% Short Ratio0.16 Perf Half Y-34.14%
Book/sh- P/B- EPS next Y-4.55% ROA- Short Interest0.00M Perf Year-74.20%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.85 - 17.48 Perf YTD-75.75%
Dividend Est.- P/FCF- EPS past 5Y-90.91% ROI- 52W High-87.53% Beta-0.81
Dividend TTM- Quick Ratio- Sales past 5Y-25.00% Gross Margin- 52W Low17.84% ATR (14)0.29
Dividend Ex-DateAug 13, 2008 Current Ratio- EPS Y/Y TTM- Oper. Margin- RSI (14)45.56 Volatility9.43% 12.73%
Employees- Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price9.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q- Payout- Rel Volume0.04 Prev Close2.20
Sales Surprise- EPS Surprise66.98% Sales Q/Q- EarningsAug 08 BMO Avg Volume14.99K Price2.18
SMA20-8.06% SMA50-4.29% SMA200-59.46% Trades Volume567 Change-0.91%
Date Action Analyst Rating Change Price Target Change
Sep-04-24Initiated H.C. Wainwright Buy $9
Oct-24-23Initiated Cantor Fitzgerald Overweight $30
Aug-08-24 08:30AM
08:00AM
Jun-04-24 07:28AM
May-23-24 09:03PM
May-22-24 08:00AM
09:40AM Loading…
May-15-24 09:40AM
Apr-25-24 09:40AM
Mar-29-24 06:00AM
Nov-17-23 07:30AM
Oct-23-23 08:12AM
Oct-03-23 12:05PM
Sep-29-23 02:46AM
Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.